RSV Treatment and Prevention
For infants and young children, nirsevimab is now the preferred prophylactic agent, administered as a single intramuscular dose before or during RSV season, replacing the older palivizumab which required monthly dosing. 1
Prophylaxis Strategy
Nirsevimab (First-Line Prevention)
Nirsevimab should be administered to:
- All infants <8 months born during or entering their first RSV season (single 50 mg dose if <5 kg; 100 mg if ≥5 kg) 1
- Children 8-19 months at increased risk for severe RSV disease entering their second season (200 mg dose) 2
This represents a major advance over palivizumab, as nirsevimab provides season-long protection with a single injection versus five monthly doses, and is recommended for all infants rather than just high-risk groups 1.
High-Risk Populations Requiring Special Attention
Children with these conditions warrant prophylaxis priority:
- Premature infants (≤35 weeks gestational age)
- Chronic lung disease of prematurity
- Hemodynamically significant congenital heart disease
- Immunocompromised states 2, 3
Palivizumab (Alternative When Nirsevimab Unavailable)
If nirsevimab is not accessible, use palivizumab 15 mg/kg IM monthly for 5 doses during RSV season, but only for the high-risk populations listed above 4, 5.
Active Treatment of RSV Infection
Supportive Care (Cornerstone of Management)
Treatment remains primarily supportive for all RSV infections:
- Oxygen supplementation for hypoxemia (maintain SpO2 >90%)
- Hydration support (IV fluids if unable to maintain oral intake)
- Respiratory support escalation as needed: nasal cannula → high-flow nasal cannula → CPAP → mechanical ventilation
- Monitoring for respiratory distress, apnea (especially in young infants), and dehydration
Ribavirin (Limited Role)
Ribavirin should be considered only for severely ill or immunocompromised patients with documented RSV lower respiratory tract infection. 6
Dosing for immunocompromised adults/children with severe disease:
- Oral or IV ribavirin: 10 mg/kg every 8 hours (maximum dose)
- Day 1: 600 mg loading dose, then 200 mg every 8 hours
- Day 2: 400 mg every 8 hours
- Day 3 onward: Increase to maximum 10 mg/kg every 8 hours 6
Dose adjustment for renal impairment:
- CrCl 30-50 mL/min: Maximum 200 mg every 8 hours
- CrCl 10-30 mL/min: No clear recommendation; some experts use 200 mg once daily with close monitoring 6
Critical caveats:
- Evidence for ribavirin efficacy is weak, based primarily on small retrospective studies and case reports 7
- Aerosolized ribavirin has the most historical data but is logistically challenging
- Systemic (oral/IV) ribavirin is preferred to limit administration complexity while managing toxicity risk 6, 7
- The role of IVIG or palivizumab as adjunctive therapy with ribavirin in immunocompromised patients remains unclear, with limited evidence suggesting possible benefit in hematopoietic stem cell transplant recipients 6, 7, 8
What NOT to Use Routinely
- Bronchodilators: May provide short-term symptomatic relief but not recommended as standard practice 9
- Corticosteroids: May be considered for moderate-to-severe cases but lack strong evidence 9
- Antibiotics: Only if bacterial superinfection is documented or strongly suspected
Key Clinical Pitfalls
Don't delay nirsevimab administration waiting for RSV season onset—give it shortly before or at season start (typically fall through spring) 1
Don't use both maternal RSV vaccination and nirsevimab in the same infant—most infants need only one preventive strategy 10
Don't routinely treat mild RSV with antivirals—ribavirin is reserved for severe disease in high-risk/immunocompromised patients only 6, 7
Don't assume nirsevimab protects beyond 5 months—children remaining at high risk in a second season need re-dosing 2
Monitor immunocompromised patients aggressively—RSV can progress to severe lower respiratory tract disease with high mortality in this population, warranting early consideration of ribavirin 6, 7